UNSPSC 51111876: Leuprorelin

This classification denotes a gonadotropin-releasing hormone analog, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier EFY6W0M8TG. European Medicines Agency schedules Leuprolide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08449MIG. Leuprolide generally arises in the molecular formula C59H84N16O12. The term 'leuprolide' is a European Pharmacopoeia designation.

UNSPSC 51111876 Leuprorelin, a Commodity code, covers the procurement of leuprorelin, a gonadotropin-releasing hormone agonist used primarily in the treatment of prostate cancer, endometriosis, and uterine fibroids in state and local healthcare systems, correctional facilities, and public health agencies. State and local governments purchase leuprorelin through their pharmacy procurement channels, typically as part of broader pharmaceutical supply agreements or specialty drug formularies managed by Medicaid programs, public hospital systems, and detention health services. The drug is procured both as individual patient fills and through standing purchase orders that consolidate demand across multiple facilities or patient populations within a jurisdiction.

The source provided contains no recent state and local contract opportunities tagged to this code, and therefore does not support characterization of issuing-body concentration, geographic distribution, or representative recent solicitations. Without posted RFP, RFQ, IFB, or ITB records, the current market activity and procurement patterns for leuprorelin cannot be assessed from available data.